Using Artificial Intelligence (AI) to Model Clinical Variant Reporting for Next Generation Sequencing (NGS) Oncology Assays
Kenneth DoigiD, Rashindrie D PereraiD, Yamuna KankanigeiD, ANDREW P. FELLOWESiD, Jason LiiD, Richard LupatiD, Ella R. ThompsoniD, Piers A. BlomberyiD, Stephen B. FoxiD
Abstract
BackgroundTargeted next generation sequencing (NGS) of somatic DNA is now routinely used for diagnostic and predictive reporting in the oncology clinic. The expert genomic analysis required for NGS assays remains a bottleneck to scaling the volume of patients being assessed. This study harnesses data from targeted clinical sequencing to build machine learning models that predict whether patient variants should be reported. MethodsThree somatic assays were used to build machine learning prediction models (Stochastic Gradient Descent, Random Forest, XGBoost and Neural Networks). Using manual expert curation to select reportable variants as ground truth, we built models to classify clinically reportable variants. Assays were performed between 2020 and 2023 yielding 1,350,018 variants and used to report on 10,116 patients. All variants, together with 211 annotations and sequencing features, were used by the models to predict the likelihood of variants being reported. ResultsThe tree-based ensemble models performed consistently well achieving between 0.891 and 0.995 on the precision recall/area under the curve (PRC AUC) metric when predicting whether a variant should be reported. To assist model explainability, individual model predictions were presented to users within a tertiary analysis platform as a waterfall plot showing individual feature contributions and their values for the variant. Over 30% of the model performance was due to features sourced from statistics derived in-house from the sequencing assay precluding easy generalization of the models to other assays or other laboratories. ConclusionsLongitudinally acquired NGS assay data provide a strong basis for machine learning models for decision support to select variants for clinical oncology reports. The models provide a framework for consistent reporting practices and reducing inter-reviewer variability. To improve model transparency, individual variant predictions are able to be presented as part of reviewer workflows.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 4
- FWCI
- 2.36
- Field percentile
- top 11%
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Using Machine Learning to Identify True Somatic Variants from Next-Generation Sequencing
Chao Wu, Xiaonan Zhao, … Mahdi Sarmady·Clinical ChemistryPeer-reviewed·Oct 31, 2019
- Validation of genetic variants from NGS data using Deep Convolutional Neural Networks
Marc Vaisband, Maria Schubert, … Jan Hasenauer·BMC BioinformaticsPeer-reviewed·Apr 20, 2023
- A fully-automated integrative workflow to streamline NGS-based analyses within Molecular Tumour Boards
Maria Giulia Carta, Miriam Angeloni, … Fulvia Ferrazzi·medRxiv·Dec 15, 2025
- Intelli-NGS: Intelligent NGS, a deep neural network-based artificial intelligence to delineate good and bad variant calls from IonTorrent sequencer data
Aditya Singh, Prateek Bhatia·bioRxiv·Dec 17, 2019
- Reporting results of diagnostic NGS-based testing - user-centered redesign of the clinical report.
Oleg Agafonov, Sigrun Vik, … Sharmini Alagaratnam·medRxiv·Mar 15, 2021
- Software-assisted manual review of clinical NGS data:an alternative to routine Sanger sequencing confirmationwith equivalent results in >15,000 hereditary cancer screens
Dale Muzzey, Shera F. Kash, … Kevin R. Haas·bioRxiv·Sep 23, 2018